Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

An all-stock transaction will see Europe’s Kiadis and US’s CytoSen bring together complementary approaches to improving stem cell transplants and cancer immunotherapy.  

Lymphocytes
Lymphocytes mediate GVHD in transplant patients. • Source: Shutterstock

The proposed acquisition of the private US biotech, CytoSen Therapeutics Inc., by the Amsterdam, Netherlands-based Kiadis Pharma Netherlands BV will produce a new company with two synergistic immunotherapy platforms, involving natural killer cells and T-cells, a cell therapy for graft-versus-host disease (GVHD) in leukemia patients nearing the market, and a strengthened position in the key US market.

“No other company has platform technologies targeting both arms of the immune system, innate and adaptive,” believes Kiadis CEO Arthur...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.